Will DaVita Kidney Care Gain On Medtronic Collaboration?

Zacks

DaVita HealthCare Partners Inc.’s (DVA) division DaVita Kidney Care, a leading provider of kidney care services, announced a joint venture with Medtronic which aims at better understanding of cardiovascular health in end-stage renal disease (ESRD) patients.

This venture will emphasize on the development of a pilot program to identify cardiac arrhythmias in patients on dialysis with the help of Medtronic's Reveal LINQ™ Insertable Cardiac Monitoring system.

Medtronic has a worldwide presence in manufacturing and selling device-based medical therapies. The company operates through three segments – Cardiac and Vascular Group, Restorative Therapies Group and Diabetes Group.

At the American Society of Nephrology meeting, Medtronic presented data that exhibited patients receiving hemodialysis to have higher incidence of arrhythmias. This collaboration is a significant step as Medtronic, along with DaVita, will be able to monitor a larger patient population. The additional data hence collected will facilitate the understanding of the relationship between dialysis and cardiac events in ESRD patients.

This collaboration will help DaVita gain the knowledge required to improve the lives of ESRD patients considering the fact that high incidence rate of cardiovascular disease and events occur in ESRD patients.

Medtronic’s innovative monitoring technology and DaVita Kidney Care’s information systems data together will help ESRD patients by dedicatedly detecting and preventing cardiac complications.

DaVita regularly acquires companies both domestically as well as internationally in order to expand its business. However, the company is recently more inclined toward international expansion. The Colorado Springs Health Partners acquisition is one of such endeavors.

Currently, DaVita carries a Zacks Rank #3 (Hold). Better-ranked stocks worth considering include Almost Family Inc. (AFAM), Amedisys Inc. (AMED) and Chemed Corp. (CHE). All of these stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply